Highlights from EULAR 2021

Highlights From EULAR 2021
This programme is provided by the Cytokine Signalling Forum and and sponsored by Lilly.

Release date: 09 June 2021
Estimated time to complete activity: 1 hour
Compatible with all modern internet browsers and mobile devices

After completing this activity, the learner will:

  • Understand the safety and efficacy data of JAK inhibitors in RA from EULAR 2021

  • Be familiar to new data on difficult-to-treat RA, pain, patient reported outcomes, and the effects of JAKinibs on pain

  • Understand any other key highlights on cytokine signaling agents from EULAR 2021

This activity is designed for rheumatologists, and other healthcare professionals involved in treating patients with inflammatory diseases.

With the continued release of new treatment data on JAK inhibitors for the management of rheumatoid arthritis and other immune mediated inflammatory diseases, this activity will highlight the key research reported at the virtual EULAR 2021 annual conference. This session will feature the latest safety and efficacy data of JAK inhibitors, followed by discussions on pain in relation to clinical remission and patient reported outcomes.

In this activity, Highlights from EULAR 2021, international experts will discuss some of the key research from EULAR 2021 for healthcare professionals and rheumatologists. The content will be discussion based and will have a focus on rheumatoid arthritis.

CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.